Erman Akkus, Medical Oncology fellow at Ankara University, shared a poston X:
“Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma.
- Acquired resistance: via secondary FGFR2 mutations in >60% of patients with clinical benefit
- low achievable drug concentrations in humans >emergence of resistance
- FGFR inhibitors should be small, high-affinity, selective
- Tinengotinib.”
More posts featuring Erman Akkus.
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
